OnKure Therapeutics Announces Promising Preclinical Data on OKI-179 in RAS-Mutated Tumor Models Presented in a Late-Breaking Session at AACR
April 08, 2022 13:00 ET
|
OnKure, Inc.
OKI-179 demonstrated chemical synthetic lethality when combined with MEK and BRAF inhibitors in RAS pathway mutated cancer models The Company plans to initiate the OKI-179-230 Phase 1b/2 trial of...
OnKure Therapeutics to Present Late-Breaking Preclinical Data on OKI-179 at the AACR Annual Meeting 2022
March 08, 2022 16:30 ET
|
OnKure, Inc.
BOULDER, Colo., March 08, 2022 (GLOBE NEWSWIRE) -- OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today...
OnKure Therapeutics Appoints Jason Leverone, CPA, as Chief Financial Officer
February 08, 2022 07:00 ET
|
OnKure, Inc.
BOULDER, Colo., Feb. 08, 2022 (GLOBE NEWSWIRE) -- OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today...